SCHEMBL21393050

SCHEMBL21393050

C=CC(=O)N1CCC(C(=O)N2CCN(C(C)=O)CC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
ALDH1A1 P00352 3/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 2/20 0.41
HTT P42858 1/20 0.41
NAMPT P43490 1/20 0.41
CNR2 P34972 1/20 0.40
HSD11B1 P28845 1/20 0.40
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ACACB O00763 3/20 0.39
ACACA Q13085 3/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22138105 0.86 HPGD (0.59) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL15948455 0.83 CYP1A2 (0.54) ALDH1A1SMN1; SMN2HPGDCYP1A2TDP1
SCHEMBL4550238 0.81 ALDH1A1 (0.60) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL13779943 0.80 CYP1A2 (0.65) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL13629811 0.80 SMN1; SMN2 (0.49) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL18415366 0.80 HPGD (0.65) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL25499129 0.78 CYP1A2 (0.61) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL29944041 0.78 HPGD (0.69) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL22138093 0.76 HPGD (0.55) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL2677916 0.76 HTT (0.53) LMNAALDH1A1TSHRSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 LMNA 1016/4885ALDH1A1 4188/4885TSHR 4601/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 LMNA 3321/4885ALDH1A1 2969/4885TSHR 4065/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 LMNA 1016/4885ALDH1A1 4188/4885TSHR 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.